Ali Ataya, MD
Critical Care Medicine · Gainesville, FLNPI 1154635928
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,446 of the $63,275 with a category attached, or 67.1%. 10 manufacturers reported payments, led by CSL Behring at 53.4% of the total. Reporting peaked in 2020 at $33,891 and has fallen 52.5% since, to $16,090 in 2025. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $1506.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$34K
- United Therapeutics Corporation$11K
- Partner Therapeutics, Inc.$9K
- Lungpacer Medical USA Inc$6K
- Merck$2K
- Astrazeneca UK Limited$1K
- plus $480 from 4 others
Across 49 payments — averaging $12,431 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$501K
- Janssen Research & Development, LLC$75K
- Insmed, Inc.$34K
What the payments were for
- Consulting fees$18,78630%
- Speaking & faculty fees$42,44667%
- Travel & lodging$1,0602%
- Food & beverage$8471%
- Education$1350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 2 | $33,815 |
| United Therapeutics Corporation | 22 | $11,475 |
| Partner Therapeutics, Inc. | 4 | $9,131 |
| Lungpacer Medical USA Inc | 1 | $5,725 |
| Merck | 5 | $1,649 |
| Astrazeneca UK Limited | 1 | $1,000 |
| Actelion Pharmaceuticals US, Inc. | 4 | $236 |
| Bayer | 1 | $200 |
| Sandoz | 1 | $23 |
| Pfizer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,275 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WinrevairSotatercept-Csrk | 205 | $3,307,923 |
| Tyvaso DpiTreprostinil | 72 | $1,720,222 |
| OpsumitMacitentan | 113 | $1,401,746 |
| Winrevair (2 Pack)Sotatercept-Csrk | 16 | $469,622 |
| UptraviSelexipag | 17 | $389,869 |
| AdempasRiociguat | 23 | $303,320 |
| Orenitram ErTreprostinil Diolamine | 26 | $196,706 |
| Ambrisentan | 63 | $175,780 |
| LeukineSargramostim | 12 | $110,086 |
| AdcircaTadalafil | 23 | $90,565 |
| Tadalafil | 87 | $20,408 |
| Sildenafil Citrate | 65 | $5,362 |
| Sirolimus | 18 | $5,294 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,660 |
| Tranexamic Acid | 51 | $3,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckWinrevair, Winrevair (2 Pack) | $1,649 | $3,777,544221 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $236 | $1,791,616130 claims |
| BayerAdempas | $200 | $303,32023 claims |
| Partner Therapeutics, Inc.Leukine | $9,131 | $110,08612 claims |
| United Therapeutics CorporationAdcirca | $11,475 | $90,56523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Gainesville
- David BecnelGainesville$64K
- Azra BihoracGainesville$10K
- Ragai MeenaGainesville$9K
- Charles HobsonGainesville$6K
- Christopher HardenGainesville$6K
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.